Related Experiment Video
Updated: Jun 6, 2025
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
Ginsenoside RK3 inhibits glioblastoma by modulating macrophage M2 polarization via the PPARG/CCL2 axis
Haiying Zhang1, Jinpeng Hu2, Xiang Zhao3
1Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110042 China.
Background:
Glioblastoma is recognized as the most aggressive form of intracranial tumor, presenting significant challenges in treatment. Recent emphasis has been placed on the potential of traditional Chinese medicine (TCM) as an adjuvant treatment for cancer.
Methods:
We employed a series of assays-including CCK8, EdU, Transwell, and neurosphere formation-to evaluate the impact of ginsenoside RK3 on the phenotype of GBM. The modulation of macrophage M2 polarization by ginsenoside RK3 was assessed through flow cytometry, immunohistochemistry, and Western blot analysis. Furthermore, we utilized sequencing analysis and network pharmacology to identify potential therapeutic targets.
Results:
Our findings reveal that ginsenoside RK3 not only inhibits the phenotype of glioblastoma cells but also suppresses tumor progression in vivo while attenuating macrophage M2 polarization within the tumor immune microenvironment. Notably, ginsenoside RK3 down-regulates PPARG expression in tumor cells, leading to decreased secretion of CCL2, which subsequently diminishes macrophage M2 polarization. Additionally, we demonstrated that combining ginsenoside RK3 with temozolomide significantly enhances the inhibition of glioblastoma's malignant characteristics and progression.
Conclusions:
This study innovatively highlights the dual mechanism of ginsenoside RK3 in glioblastoma treatment: it impedes tumor progression by modulating the PPARG/CCL2 pathway and enhances the efficacy of temozolomide. Our research underscores the promising role of herbal medicine in the management of glioblastoma, paving the way for novel therapeutic strategies that integrate traditional approaches with conventional treatments.
Insights
Ginsenoside RK3, a traditional Chinese medicine, inhibits glioblastoma (GBM) progression by targeting the PPARG/CCL2 pathway and enhancing temozolomide efficacy. This offers a novel adjuvant therapy for aggressive brain tumors.
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment options.
- Traditional Chinese Medicine (TCM) shows promise as an adjuvant cancer therapy.
Purpose of the Study:
- To investigate the anti-GBM effects of ginsenoside RK3.
- To elucidate the underlying mechanisms, including immune modulation.
- To assess its potential in combination therapy.
Main Methods:
- Cell-based assays (CCK8, EdU, Transwell, neurosphere formation) and in vivo studies.
- Flow cytometry, immunohistochemistry, and Western blot for M2 macrophage polarization.
- Sequencing and network pharmacology for target identification.
Main Results:
- Ginsenoside RK3 inhibited GBM cell phenotype and suppressed tumor growth in vivo.
- It attenuated M2 macrophage polarization by down-regulating PPARG and CCL2.
- Combination with temozolomide enhanced anti-GBM effects.
Conclusions:
- Ginsenoside RK3 exhibits a dual mechanism against GBM via the PPARG/CCL2 pathway and immune modulation.
- It enhances temozolomide efficacy, suggesting a novel adjuvant therapeutic strategy.
- Herbal medicine integration offers promising avenues for glioblastoma management.
More Related Videos
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
